Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 592.65Cr 528.28Cr 489.37Cr 444.95Cr 834.94Cr 56TCr 848.67Cr 5.87TCr 2.31TCr 29TCr 2.22TCr 2.18TCr 94TCr P/E 2026 *
56.4x
P/E 2027 * 34.6x
Enterprise Value 592.65Cr 528.28Cr 489.37Cr 444.95Cr 834.94Cr 56TCr 848.67Cr 5.87TCr 2.31TCr 29TCr 2.22TCr 2.18TCr 94TCr EV / Sales 2026 *
20.5x
EV / Sales 2027 * 15.5x
Free-Float
97.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.27%
1 week-4.45%
Current month-4.83%
1 month+4.86%
3 months-2.01%
6 months+28.24%
Current year+57.23%
1 week 292.28
Extreme 292.28
307.11
1 month 281.74
Extreme 281.7401
317.23
Current year 175.89
Extreme 175.89
326.63
1 year 175.89
Extreme 175.89
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 65 01/03/2007
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Exercice

General Counsel

5,680 0.0285%
22/09/26 Tax

Director

-115 0.0006%
10/09/26 Sell

Director

-1,200 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-4.45%+63.66%+463.24% 592.65Cr
+3.33%+4.88%+54.50%+109.94% 1,10600Cr
+2.08%-3.77%+31.35%+66.62% 61TCr
+1.58%+0.55%+23.13%+94.26% 50TCr
+1.84%+7.20%+37.21%+61.38% 37TCr
+3.04%-1.25%+69.39%+43.02% 35TCr
+1.27%+5.13%+20.43%+47.90% 29TCr
+1.40%+4.89%-0.68%+19.64% 26TCr
+1.72%+1.76%+42.21%+51.44% 23TCr
+2.14%+1.75%+24.64%+95.14% 19TCr
Average +1.79%+1.47%+36.58%+105.26% 39.06TCr
Weighted average by Cap. +2.27%+2.29%+38.32%+76.42%

Financials

2026 *2027 *
Net sales 29Cr 26Cr 24Cr 22Cr 41Cr 2.74TCr 41Cr 286.15Cr 112.52Cr 1.43TCr 108.4Cr 106.13Cr 4.58TCr 38Cr 34Cr 32Cr 29Cr 54Cr 3.62TCr 55Cr 378Cr 148.64Cr 1.89TCr 143.19Cr 140.2Cr 6.05TCr
Net income 11Cr 10Cr 9.29Cr 8.45Cr 16Cr 1.07TCr 16Cr 111.42Cr 44Cr 557.48Cr 42Cr 41Cr 1.78TCr 19Cr 17Cr 15Cr 14Cr 26Cr 1.78TCr 27Cr 185.87Cr 73Cr 929.94Cr 70Cr 69Cr 2.97TCr
Net Debt - -
Projected Income Statement - Annual - Ligand Pharmaceuticals Incorporated
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
20/26/20 $297.28 +0.59% 1,16,995
16/26/16 $295.54 -0.99% 1,64,510
15/26/15 $298.50 +1.19% 3,32,111
14/26/14 $294.99 -2.81% 2,45,284
13/26/13 $303.53 -2.44% 1,96,563
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ligand Pharmaceuticals Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
297.28USD
Average target price
345.75USD
Spread / Average Target
+16.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ligand Pharmaceuticals Incorporated
  1. Stock Market
  2. Stocks
  3. LGND Stock